Bortezomib in previously treated phosphatase and tension homology‐deficient patients with advanced intrahepatic cholangiocarcinoma: An open‐label, prospective and single‐centre phase II trial

Abstract Introduction Intrahepatic cholangiocarcinoma (ICC) is characterized by a dismal prognosis with limited therapeutic alternatives. To explore phosphatase and tension homolog (PTEN) as a biomarker for proteasome inhibition in ICC, we conducted a phase II trial to assess the second‐line efficac...

Descripció completa

Dades bibliogràfiques

Autors principals:	Tian‐mei Zeng, Tian‐yi Jiang, Guang Yang, Zhuo Cheng, Cheng Lou, Wei Wei, Chen‐jie Tao, Shouzi Hu, Hui Wang, Xiao‐wen Cui, Ye‐xiong Tan, Li‐wei Dong, Hong‐yang Wang, Zhen‐gang Yuan
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2024-05-01
Col·lecció:	Clinical and Translational Medicine
Matèries:	bortezomib intrahepatic cholangiocarcinoma PTEN
Accés en línia:	https://doi.org/10.1002/ctm2.1675
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!